To examine the effect of DR3 signaling on intestinal ILCs, we treated mice with an α-DR3 agonistic antibody (4C12), which has been shown to boost Tregs and may be implicated in treatment of autoimmune diseases. This evidence concerns the gene TNFRSF25 and autoimmune disease.